思路迪医药股份二零二四年年报

2024ANNUAL REPORT年度報告 Contents 2Definitions8Corporate Information11Chairman’s Statement14Financial Summary15Management Discussion and Analysis48Biographies of Directors and Senior Management59Corporate Governance Report81Report of Directors114Environmental, Social and Governance Report193Independent Auditor’s Report201Consolidated Statements of Profit or Loss andOther Comprehensive Income202Consolidated Statement of Financial Position204Consolidated Statement of Changes in Equity206Consolidated Statement of Cash Flows209Notes to Financial Statements Corporate Information BOARD OF DIRECTORS Executive DirectorDr. Gong Zhaolong(Chairman of the Board) Non-executive Directors Mr. Zhu PaiMr. Zhou FengMs. Chen Yawen Independent Non-executive Directors Li Jin Dr. Li JinDr. Lin Tat PangMr. Liu Xinguang REMUNERATION COMMITTEE Li Jin Mr. Liu Xinguang(Chairman)Dr. Gong ZhaolongDr. Li Jin NOMINATION COMMITTEE Li Jin20253312025331 Dr. Gong Zhaolong(Chairman)Dr. Li JinMr. Liu XinguangMs. Chen Yawen(was appointed on March 31, 2025)Dr. Lin Tat Pang(was appointed on March 31, 2025) AUDIT COMMITTEE Li Jin Dr. Lin Tat Pang(Chairman)Mr. Zhu PaiDr. Li Jin JOINT COMPANY SECRETARIES Ms. Xia FangMs. Li Ching Yi AUTHORISED REPRESENTATIVES Dr. Gong ZhaolongMs. Li Ching Yi LEGAL ADVISERS 131 As to Hong Kong law:O’Melveny & Myers31/F, AIA Central1 Connaught Road CentralHong Kong As to PRC law: Zhong Lun Law Firm6/10/11/16/17F, Two IFC8 Century AvenuePudong New AreaShanghaiPRC 86/10/11/16/17 As to Cayman Islands laws: 829 Conyers Dill & Pearman29th FloorOne Exchange Square8 Connaught PlaceCentralHong Kong AUDITOR AND REPORTING ACCOUNTANT 288 Modern Assure CPA LimitedCertified Public AccountantsRegistered Public Interest Entity AuditorsUnit B, 14/F, Eton Building288 Des Voeux Road CentralSheung WanHong Kong STOCK CODE 1244 1244 PRINCIPAL BANK 15822F3 Bank of CommunicationsShanghai Minhang Sub-branch22F, Block 3, Jiefang TowerNo. 158 Zhucheng RoadMinhang District, Shanghai PRC Corporate Information COMPANY WEBSITEwww.3d-medicines.com www.3d-medicines.com REGISTERED OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands CORPORATE HEADQUARTERS 35 No. 3 and No. 5, Laiyang RoadQingdao, Shandong, PRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG 18819 19/F, Golden Centre188 Des Voeux Road CentralHong Kong PRINCIPAL SHARE REGISTRAR ANDTRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands HONG KONG BRANCH SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong Dear Shareholders, 3 DMedicinesInc.20241231 Onbehalf of the Board of Directors,I am pleased to present theannual report of 3D Medicines Inc. for the year ended December 31,2024. 2024 Guidedby the long-term strategic goals of sustainable growthandglobal expansion,our company continues to strengthen itsresearch and development capabilities. During the reporting periodand up to the date of this announcement, the company recorded amodest revenue decline, yet demonstrated an improving trend withsignificantlyenhanced operational efficiency,and made importantprogressin subsequent events and early-stage R&D platforms,including: Chairman’s Statement 2024®445.629.8%202415.9%133D1015mRNA(LNP)®E S G Stable Product Revenue: For the year of 2024, revenue from the salesof®decreasedby 29.8%due to fierce market competition.However,sales in the second half of 2024 increased by 15.9%compared to sales in the first half of the year, reflecting a positiveturnaroundin sales trend.The company reduced ManagementCosts,further improved workforce efficiency,and diversified theproductpipeline with 13 products,including the newly addedradiopharmaceuticaldrug conjugate(RDC)3D1015.Progresswasmade in the mRNA drug R&D platform,establishing in-houseintellectualproperty(IP)-protected lipid nanoparticle(LNP)library.®achievedmultiple advancements in clinical development,commercialization,and international expansion.Its high qualitypreclinical and clinical research results were published in prestigiousacademicconferences and journals,and it was continuouslyaddedto authoritative clinical guidelines and expert consensusrecommendations. It has also integrated Environmental, Social, andGovernance(ESG)into its daily operations.During the reportingperiod,we continuously explored the potential for product pipelinedevelopmentand combination mechanisms,adding momentum toglobal innovation and long-term sustainable growth. 2024445.6180.7202357.5%20241231864.3444.3® Ourfinancial performance in 2024 reflects our strong operationalexecution and prudent